Faron Pharmaceuticals Advances Bexmarilimab with New Phase II Trial and Promising ASH Data in Blood Cancers
核心洞察
Faron Pharmaceuticals (搜索) announced the Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in AML patients with measurable residual disease after stem cell transplantation, targeting a critical unmet need in preventing relapse.
Updated BEXMAB study data presented at ASH 2025 showed median overall survival of 14.5 months in relapsed/refractory HR-MDS patients, significantly improving upon the historical 5-6 month survival rate.
The combination achieved remarkable 70% complete remission rates in treatment-naïve HR-MDS patients with TP53 mutations, with 50% proceeding to potentially curative stem cell transplant.
Faron Pharmaceuticals (搜索) has announced significant progress in its clinical development program for bexmarilimab, an investigational immunotherapy targeting the Clever-1 (搜索) receptor, with the launch of a new Phase II trial and presentation of encouraging efficacy data in blood cancers.
The Finnish biopharmaceutical company revealed the upcoming initiation of the Phase II BEAM-X Investigator-Initiated Trial, led by the Nordic AML Group (搜索) with Dr. Mika Kontro as principal investigator. The trial will evaluate bexmarilimab in combination with azacitidine for patients with measurable residual disease (MRD) positive acute myeloid leukemia following allogeneic stem cell transplantation.
Addressing Critical Unmet Need in Post-Transplant AML
Relapse after transplantation represents one of the most devastating challenges for AML patients, driven largely by the persistence or return of MRD, which serves as the strongest predictor of full leukemia relapse. Despite advances in transplant medicine, therapeutic options for MRD-positive patients after stem cell transplantation remain limited.
"Preventing relapse after transplantation is one of the greatest unmet needs in AML," said Dr. Petri Bono, Chief Medical Officer of Faron. "The complementary biology of azacitidine and bexmarilimab makes this combination particularly compelling in the MRD setting, where timely immune activation may meaningfully alter the clinical trajectory."
The BEAM-X trial targets the MRD phase when disease burden is low and immune-mediated elimination is biologically most achievable. By combining azacitidine's ability to enhance antigen presentation with bexmarilimab's restoration of immune activation, the combination aims to create conditions for early immune-mediated clearance of residual disease and reduce relapse risk.
Trial Design and Timeline
The open-label, two-stage Phase II trial will enroll 24 patients and aims for a primary endpoint of MRD negativity at six months. Key secondary endpoints include relapse-free survival, overall survival, safety and tolerability, and incidence of graft-versus-host disease. Patients may receive short venetoclax intensification if MRD kinetics remain suboptimal.
First patient enrollment is expected in Q3 2026, with the initial stage-1 efficacy readout anticipated 12-15 months after enrollment begins.
"Patients who develop MRD after stem cell transplantation face a very high risk of relapse and poor survival, and we urgently need new strategies that intervene earlier and more effectively," said Dr. Mika Kontro, trial Principal Investigator at Helsinki University Hospital (搜索).
Promising ASH 2025 Data in HR-MDS
Supporting the BEAM-X rationale, Faron presented updated data from its Phase I/II BEXMAB study at the American Society of Hematology (ASH) 2025 Annual Meeting, demonstrating significant improvements in survival outcomes for patients with higher-risk myelodysplastic syndromes (HR-MDS).
The median overall survival with bexmarilimab and azacitidine in relapsed/refractory HR-MDS patients reached 14.5 months, increased from 13.4 months observed earlier and representing a significant improvement in a population with historically poor survival of only 5-6 months.
Exceptional Results in TP53-Mutated Patients
The combination showed particularly strong efficacy in patients with TP53 mutations, a genetic profile typically associated with resistance to standard therapies. In treatment-naïve patients with HR-MDS and TP53 mutation, the combination achieved a remarkable 70% complete remission rate.
Dr. Amer Zeidan, Professor of Internal Medicine at Yale University and chief of Hematologic Malignancies at Yale Cancer Center, commented: "Observing a median overall survival of 14.5 months in the relapsed setting, together with the notably high complete remission rates in frontline TP53-mutated disease represents a highly encouraging signal of efficacy."
Deep responses enabled 50% of treatment-naïve TP53-mutated patients and 21% of relapsed/refractory TP53-mutated patients to proceed to stem cell transplant, potentially offering a bridge to curative therapy.
Restoration of Bone Marrow Function
For the first time, data showed 57% of frontline patients who were transfusion-dependent at baseline achieved transfusion independence, confirming restoration of healthy bone marrow function. Across the entire HR-MDS BEXMAB trial population, 23% of dependent patients converted to independence, with maintenance of transfusion independence robust at 65%.
"By demonstrating that we can convert over half of frontline transfusion dependent patients to independence, while simultaneously driving deep molecular remissions in high-risk genetic subgroups, we are confirming that bexmarilimab acts on cancer cells and actively rehabilitates the bone marrow environment," said Dr. Bono.
Safety Profile and Future Development
The combination continues to demonstrate an excellent safety profile, with no Grade 5 bexmarilimab-related adverse events across the HR-MDS cohort. The encouraging safety profile and clear efficacy signals support bexmarilimab's advancement into a randomized Phase 3 registrational trial.
Bexmarilimab works by targeting Clever-1 (搜索), a receptor on immunosuppressive macrophages and malignant blasts. By inhibiting Clever-1, the drug reprograms the tumor microenvironment from an immunosuppressive state to an immunostimulatory one, igniting a potent anti-tumor immune response and sensitizing cancer cells to standard treatments.